Beta adrenergic receptor kinase-2
Beta Adrenergic Receptor Kinase-2[edit | edit source]
Beta Adrenergic Receptor Kinase-2 (BARK2), also known as GRK3 (G protein-coupled receptor kinase 3), is an enzyme that plays a critical role in the regulation of G protein-coupled receptors (GPCRs). It is part of the GRK family, which is involved in the desensitization of GPCRs, a process crucial for maintaining cellular responsiveness to external signals.
Structure[edit | edit source]
BARK2 is a serine/threonine kinase that shares structural similarities with other members of the GRK family. It consists of several domains, including an N-terminal domain, a central catalytic domain, and a C-terminal domain that is involved in membrane association and protein-protein interactions.
Function[edit | edit source]
The primary function of BARK2 is to phosphorylate activated GPCRs, leading to the recruitment of beta-arrestins. This recruitment initiates receptor desensitization, internalization, and downregulation, thereby modulating the receptor's signaling capacity. BARK2 is particularly important in the regulation of beta-adrenergic receptors, which are involved in the physiological response to catecholamines like adrenaline and noradrenaline.
Clinical Significance[edit | edit source]
Alterations in BARK2 activity have been implicated in various pathological conditions. For instance, dysregulation of BARK2 has been associated with heart failure, where impaired desensitization of beta-adrenergic receptors can lead to excessive cardiac stimulation. Additionally, BARK2 has been studied in the context of psychiatric disorders and addiction, where it may influence neurotransmitter signaling pathways.
Research and Therapeutic Potential[edit | edit source]
Research into BARK2 and its role in GPCR regulation continues to be a significant area of interest. Understanding the precise mechanisms of BARK2 action could lead to the development of novel therapeutic strategies for conditions such as heart failure and other diseases involving GPCR dysregulation. Inhibitors of BARK2 are being explored as potential therapeutic agents to modulate GPCR signaling in various diseases.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD